KalVista Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KalVista Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2024 | $50.00M | Jul 10, 2025 |
| FY2018 | Apr 30, 2018 | $4.84M | Jul 30, 2018 |
| FY2018 | Jan 31, 2018 | $2.33M | Jul 30, 2018 |
| FY2018 | Oct 31, 2017 | $1.13M | Jul 30, 2018 |
| FY2018 | Jul 31, 2017 | $96.0K | Jul 30, 2018 |
| FY2018 | Apr 30, 2017 | $114.0K | Jul 30, 2018 |
| FY2018 | Jan 31, 2017 | $248.0K | Jul 30, 2018 |
| FY2018 | Oct 31, 2016 | $197.0K | Jul 30, 2018 |
| FY2018 | Jul 31, 2016 | $975.0K | Jul 30, 2018 |
| FY2018 | Apr 30, 2016 | $2.13M | Jul 30, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Apr 30, 2020 | $3.82M | Jul 1, 2020 |
| FY2020 | Jan 31, 2020 | $1.58M | Jul 1, 2020 |
| FY2020 | Oct 31, 2019 | $3.92M | Jul 1, 2020 |
| FY2020 | Jul 31, 2019 | $3.37M | Jul 1, 2020 |
| FY2020 | Apr 30, 2019 | $2.93M | Jul 1, 2020 |
| FY2020 | Jan 31, 2019 | $3.89M | Jul 1, 2020 |
| FY2020 | Oct 31, 2018 | $5.59M | Jul 1, 2020 |
| FY2020 | Jul 31, 2018 | $3.72M | Jul 1, 2020 |
| FY2019 | Apr 30, 2018 | $4.84M | Jul 16, 2019 |
| FY2019 | Jan 31, 2018 | $2.33M | Jul 16, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($183.44M) | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | ($126.64M) | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | ($92.91M) | Jul 11, 2024 |
| FY2024 | Apr 30, 2022 | ($82.34M) | Jul 11, 2024 |
| FY2023 | Apr 30, 2021 | ($46.24M) | Jul 10, 2023 |
| FY2020 | Apr 30, 2020 | ($6.59M) | Jul 1, 2020 |
| FY2020 | Jan 31, 2020 | ($9.29M) | Jul 1, 2020 |
| FY2020 | Oct 31, 2019 | ($5.90M) | Jul 1, 2020 |
| FY2020 | Jul 31, 2019 | ($7.34M) | Jul 1, 2020 |
| FY2020 | Apr 30, 2019 | ($8.53M) | Jul 1, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($188.00M) | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | ($140.45M) | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | ($110.87M) | Jul 11, 2024 |
| FY2024 | Apr 30, 2022 | ($96.61M) | Jul 11, 2024 |
| FY2023 | Apr 30, 2021 | ($57.92M) | Jul 10, 2023 |
| FY2022 | Apr 30, 2020 | ($40.53M) | Jul 7, 2022 |
| FY2021 | Apr 30, 2019 | ($29.82M) | Jul 13, 2021 |
| FY2020 | Apr 30, 2018 | ($18.71M) | Jul 1, 2020 |
| FY2019 | Apr 30, 2017 | ($22.34M) | Jul 16, 2019 |
| FY2018 | Apr 30, 2016 | ($15.18M) | Jul 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $71.71M | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | $86.17M | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | $80.28M | Jul 11, 2024 |
| FY2024 | Apr 30, 2022 | $70.17M | Jul 11, 2024 |
| FY2023 | Apr 30, 2021 | $41.29M | Jul 10, 2023 |
| FY2022 | Apr 30, 2020 | $40.19M | Jul 7, 2022 |
| FY2021 | Apr 30, 2019 | $35.02M | Jul 13, 2021 |
| FY2020 | Apr 30, 2018 | $18.24M | Jul 1, 2020 |
| FY2019 | Apr 30, 2017 | $12.67M | Jul 16, 2019 |
| FY2018 | Apr 30, 2016 | $14.66M | Jul 30, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($152.91M) | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | ($89.23M) | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | ($75.26M) | Jul 11, 2024 |
| FY2024 | Apr 30, 2022 | ($78.13M) | Jul 11, 2024 |
| FY2023 | Apr 30, 2021 | ($30.17M) | Jul 10, 2023 |
| FY2022 | Apr 30, 2020 | ($44.82M) | Jul 7, 2022 |
| FY2021 | Apr 30, 2019 | ($36.37M) | Jul 13, 2021 |
| FY2020 | Apr 30, 2018 | $10.56M | Jul 1, 2020 |
| FY2019 | Apr 30, 2017 | ($23.72M) | Jul 16, 2019 |
| FY2018 | Apr 30, 2016 | ($13.16M) | Jul 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $434.0K | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | $42.0K | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | $1.20M | Jul 11, 2024 |
| FY2024 | Apr 30, 2022 | $931.0K | Jul 11, 2024 |
| FY2023 | Apr 30, 2021 | $82.0K | Jul 10, 2023 |
| FY2022 | Apr 30, 2020 | $220.0K | Jul 7, 2022 |
| FY2021 | Apr 30, 2019 | $1.08M | Jul 13, 2021 |
| FY2020 | Apr 30, 2018 | $1.43M | Jul 1, 2020 |
| FY2019 | Apr 30, 2017 | $74.0K | Jul 16, 2019 |
| FY2018 | Apr 30, 2016 | $11.0K | Jul 30, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $250.77M | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | $235.40M | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | $183.20M | Jul 11, 2024 |
| FY2023 | Apr 30, 2022 | $203.88M | Jul 10, 2023 |
| FY2022 | Apr 30, 2021 | $272.01M | Jul 7, 2022 |
| FY2021 | Apr 30, 2020 | $92.53M | Jul 13, 2021 |
| FY2020 | Apr 30, 2019 | $118.13M | Jul 1, 2020 |
| FY2019 | Apr 30, 2018 | $61.39M | Jul 16, 2019 |
| FY2018 | Apr 30, 2017 | $34.35M | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | $24.75M | Jul 27, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $7.48M | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $11.27M | Mar 30, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $95.39M | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | $206.58M | Jul 10, 2025 |
| FY2025 | Apr 30, 2023 | $161.03M | Jul 10, 2025 |
| FY2024 | Apr 30, 2022 | $185.09M | Jul 11, 2024 |
| FY2024 | Apr 30, 2021 | $257.19M | Jul 11, 2024 |
| FY2023 | Apr 30, 2020 | $83.75M | Jul 10, 2023 |
| FY2022 | Apr 30, 2019 | $96.74M | Jul 7, 2022 |
| FY2021 | Apr 30, 2018 | $27.25M | Jul 13, 2021 |
| FY2020 | Apr 30, 2017 | $31.33M | Jul 1, 2020 |
| FY2019 | Apr 30, 2016 | ($37.11M) | Jul 16, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($653.17M) | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | ($469.73M) | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | ($343.08M) | Jul 11, 2024 |
| FY2023 | Apr 30, 2022 | ($250.18M) | Jul 10, 2023 |
| FY2022 | Apr 30, 2021 | ($167.84M) | Jul 7, 2022 |
| FY2021 | Apr 30, 2020 | ($121.59M) | Jul 13, 2021 |
| FY2020 | Apr 30, 2019 | ($92.48M) | Jul 1, 2020 |
| FY2019 | Apr 30, 2018 | ($71.66M) | Jul 16, 2019 |
| FY2018 | Apr 30, 2017 | ($55.86M) | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | ($37.25M) | Jul 27, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $131.62M | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | $31.79M | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | $56.24M | Jul 11, 2024 |
| FY2023 | Apr 30, 2022 | $30.73M | Jul 10, 2023 |
| FY2022 | Apr 30, 2021 | $50.59M | Jul 7, 2022 |
| FY2021 | Apr 30, 2020 | $15.79M | Jul 13, 2021 |
| FY2020 | Apr 30, 2019 | $32.01M | Jul 1, 2020 |
| FY2019 | Apr 30, 2018 | $51.06M | Jul 16, 2019 |
| FY2019 | Apr 30, 2017 | $30.95M | Jul 16, 2019 |
| FY2019 | Apr 30, 2016 | $21.76M | Jul 16, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | (3) | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | (3) | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | (3) | Jul 11, 2024 |
| FY2024 | Apr 30, 2022 | (3) | Jul 11, 2024 |
| FY2023 | Apr 30, 2021 | (2) | Jul 10, 2023 |
| FY2022 | Apr 30, 2020 | (1) | Jul 7, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | (3) | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | (3) | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | (3) | Jul 11, 2024 |
| FY2024 | Apr 30, 2022 | (3) | Jul 11, 2024 |
| FY2023 | Apr 30, 2021 | (2) | Jul 10, 2023 |
| FY2022 | Apr 30, 2020 | (1) | Jul 7, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 49.76M | Jul 10, 2025 |
| FY2025 | Apr 30, 2024 | 42.52M | Jul 10, 2025 |
| FY2024 | Apr 30, 2023 | 34.17M | Jul 11, 2024 |
| FY2023 | Apr 30, 2022 | 24.55M | Jul 10, 2023 |
| FY2022 | Apr 30, 2021 | 24.42M | Jul 7, 2022 |
| FY2021 | Apr 30, 2020 | 17.85M | Jul 13, 2021 |
| FY2020 | Apr 30, 2019 | 17.28M | Jul 1, 2020 |
| FY2019 | Apr 30, 2018 | 10.80M | Jul 16, 2019 |
| FY2018 | Apr 30, 2017 | 9.71M | Jul 30, 2018 |
| FY2017 | Apr 30, 2016 | 0 | Jul 27, 2017 |